Status:
COMPLETED
Non-Interventional Study on the Tolerability and Efficacy of IVIG
Lead Sponsor:
Octapharma
Conditions:
Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG
Eligibility:
All Genders
Brief Summary
Non-Interventional Study on the Tolerability and Efficacy of octagam® 10%
Detailed Description
A Non-Interventional Study on the Tolerability and Efficacy of Octagam 5% or 10% or panzyga. Patients with any indication (replacement and immonomodulation) as prescribed by the treating physician. Ma...
Eligibility Criteria
Inclusion
- Any patient who needs to be treated with a product of this class because of his/her medical condition and whom the treating physician decides to prescribe Octagam or panzyga regularly, may be included.
Exclusion
- None
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 5 2020
Estimated Enrollment :
344 Patients enrolled
Trial Details
Trial ID
NCT02303093
Start Date
August 1 2011
End Date
June 5 2020
Last Update
June 29 2021
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Octapharma Research Site
Gmunden, Austria, 17 4810
2
Octapharma Research Site
Graz, Austria, 22 8036
3
Octapharma Research Site
Klagenfurt, Austria, 35 9020
4
Octapharma Research Site
Oberndorf, Austria, 56 5110